Varicella-zoster virus vaccine was shown to boost VZV-specific immunity, which is thought to be the mechanism by which it protects against zoster and its complications.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J07BK02 | Zoster, live attenuated | J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BK Varicella zoster vaccines |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| ZOSTAVAX Powder and solvent for suspension for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Attenuated varicella-zoster virus is an active ingredient of these brands:
United States (US)
Austria (AT)
Brazil (BR)
Canada (CA)
Croatia (HR)
Cyprus (CY)
Estonia (EE)
France (FR)
Hong Kong (HK)
Ireland (IE)
Israel (IL)
Italy (IT)
Lithuania (LT)
Netherlands (NL)
New Zealand (NZ)
Poland (PL)
Singapore (SG)
South Africa (ZA)
Spain (ES)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
